172927-65-0

Basic information

• Product Name: Sibrafiban
• Synonyms: Sibrafiban;WBNUCLPUOSXSNJ-UHFFFAOYSA-N
• CAS NO: 172927-65-0
• Molecular Formula: C20H28N4O6
• Molecular Weight: 420.463
• Mol File: 172927-65-0.mol
• Article Data: 3

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.33g/cm³
• Refractive Index: 1.598
• CAS DataBase Reference: Sibrafiban(CAS DataBase Reference)
• NIST Chemistry Reference: Sibrafiban(172927-65-0)
• EPA Substance Registry System: Sibrafiban(172927-65-0)

Safety Data

• Hazardous Substances Data: 172927-65-0(Hazardous Substances Data)

Usage

Uses

Antithrombotic; fibrinogen receptor antagonist; platelet aggregation inhibitor.

InChI:InChI=1/C20H28N4O6/c1-3-29-17(25)12-30-16-8-10-24(11-9-16)20(27)13(2)22-19(26)15-6-4-14(5-7-15)18(21)23-28/h4-7,13,16,28H,3,8-12H2,1-2H3,(H2,21,23)(H,22,26)/t13-/m0/s1

Upstream product

• 170096-59-0 (1-{2-[4-(N-hydroxycarbamimidoyl)-benzoylamino]-propionyl}-piperidin-4-yloxy)-acetic acid tert-butyl ester 
• 351184-42-4 9H-fluoren-9-ylmethyl 4-hydroxy-1-piperidinecarboxylate 
• 351184-43-5 4-cyano-N-[2-(4-hydroxy-piperidin-1-yl)-1-methyl-2-oxo-ethyl]-benzamide 
• 178601-16-6 {1-[(S)-2-(4-Cyano-benzoylamino)-propionyl]-piperidin-4-yloxy}-acetic acid tert-butyl ester 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 64-17-5 ethanol 
• 178740-38-0 (1-{2-[4-(N-hydroxycarbamimidoyl)-benzoylamino]-propionyl}-piperidin-4-yloxy)-acetic acid 
• 6068-72-0 4-cyanobenzoyl chlorIde 
• 178740-38-0 Ro 48-3656 
• 170096-59-0 (1-{(S)-2-[4-(N-Hydroxycarbamimidoyl)-benzoylamino]-propionyl}-piperidin-4-yloxy)-acetic acid tert-butyl ester 

Relevant articles and documents

Process for the preparation of mixed anhydrides

The present invention is concerned with an improved process for the manufacture of mixed anhydrides. The process comprises adding an adjuvant base to a mixture of acid and reactive acid derivative. It is especially suitable for use in the synthesis of pep

Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines

The potent and selective GP IIb-IIIa antagonist lamifiban (1, Ro 44- 9883) is currently in clinical development as an injectable antithrombotic agent for treating and preventing acute coronary syndromes. However, for secondary prevention of thrombotic occlusions, orally active inhibitors are needed. By means of a prodrug strategy, the modest oral absorption of 1 in mice was improved by a factor of 9. In addition, these studies demonstrated that an amidoxime group can serve as a prodrug functionality for an amidino group. Application of this principle to the structurally related amidino carboxylate 13 led to the amidoxime ester 18 which was absorbed approximately 20 times better, after oral administration to mice, than 13. Due to the modification of the amidino group as well as of the carboxylate group, 18 completely lost its ability to interact with purified platelet GP IIb-IIIa. After oral administration of 18 to rats, dogs, and rhesus monkeys, the bioavailability of the active derivative 13 was 26 ± 5, 25 ± 6, and 33 ± 6%, respectively, and the elimination half-life was 4.1 ± 1.7, 11.4 ± 1.1, and 5.1 ± 1.4 h, respectively. On the basis of these properties, the orally active 18 (Ro 48-3657), a double prodrug of the potent and selective non- peptide GP IIb-IIIa antagonist 13 (Ro 44-3888), was selected as clinical candidate for evaluation as a prophylactic agent in patients at high risk for arterial thrombosis.